Outsourced Pharma: ADC Capacity Update

Recently Petra Dieterich Ph.D, Senior Vice President at Abzena spoke to Outsourced Pharma about our ADC services and solutions, as well as capacity updates.

In the presentation Petra spoke about the crucial role that CDMOs like Abzena are playing in the development and manufacturing of Antibody-Drug Conjugates (ADCs). ADCs are groundbreaking therapies. They combine monoclonal antibodies with cancer cell-targeting payloads. Together they offer precisely targeted and powerful anticancer effects.

ADCS are at forefront of oncology advancements. Abzena are a leading CRO and CDMO that specializes in the development and manufacture of complex biologics and bioconjugates, such as ADCs. We seamlessly integrate early R&D with comprehensive cGMP manufacturing capabilities in biologics, chemistry, and conjugation. Through this integration, and our unique experience, we consistently deliver high-quality products and data that support our partners’ regulatory submissions and product requirements.

Too here what Petra had to say, please visit the link below.

Read the article in full here